Oncolytic viruses hold much promise as novel therapeutic agents that can be combined with conventional therapeutic modalities. Measles virus (MV) is known to enter cells using the signaling lymphocyte activation molecule (SLAM), which is expressed on cells of the immune system. Although human breast cancer cell lines do not express SLAM, we found that a wild-type MV (HL strain) efficiently infected various breast cancer cell lines, causing cell death. Based on this finding, we used reverse genetics to generate a recombinant MV selectively unable to use SLAM (rMV-SLAMblind). The rMV-SLAMblind lacked infectivity for SLAM-positive lymphoid cells, while retaining oncolytic activity against breast cancer cells. We showed that, unlike the MV vaccine strains, rMV-SLAMblind used PVRL4 (polio virus receptor-related 4) as a receptor to infect breast cancer cells and not the ubiquitously expressed CD46. Consistent with this, rMV-SLAMblind infected CD46-positive primary normal human cells at a much-reduced level, whereas a vaccine strain of the Edmonston lineage (rMV-Edmonston) efficiently infected and killed them. The rMV-SLAMblind showed antitumor activity against human breast cancer xenografts in immunodeficient mice. The oncolytic activity of rMVSLAMblind was significantly greater than that of rMV-Edmonston. To assess the in vivo safety, three monkeys seronegative for MV were inoculated with rMV-SLAMblind, and no clinical symptoms were documented. On the basis of these results, rMV-SLAMblind could be a promising candidate as a novel oncolytic virus for breast cancer treatment.
INTRODUCTION
Breast cancer is the most prevalent cancer in the world and the leading cause of cancer-related deaths in women. 1 Despite recent improvements in detection and treatment, when metastasis occurs it is generally difficult to treat by conventional therapies. 2 Therefore, the development of new therapeutic strategies is clearly needed.
Oncolytic virotherapy holds much promise as a novel strategy for cancer treatment that can be combined with conventional therapies. Currently, a wide variety of viruses from many virus families are being evaluated as oncolytic agents both at the preclinical and clinical level. 3 Measles virus (MV, genus Morbillivirus, family Paramyxoviridae) is an enveloped virus with a nonsegmented, negative-strand RNA genome. 4 In contrast to retroviruses and some DNA viruses, MV replicates entirely in the cytoplasm 4 and the risk of viral sequences integrating into host chromosomal DNA is eliminated. Recently, live attenuated MV Edmonston vaccine strain derivatives have been investigated as potential oncolytic agents for various types of cancer. [5] [6] [7] [8] Three cellular proteins have been identified as MV receptors. Signaling lymphocyte activation molecule (SLAM) is predominantly expressed on cells of the immune system. [9] [10] [11] SLAM serves as a receptor for both wild-type and vaccine strains of MV. CD46 is ubiquitously expressed on all human cells except erythrocytes. 12, 13 CD46 serves as a receptor only for MV vaccine strains. Polio virus receptor-related 4 (PVRL4) has recently been identified as an epithelial cell receptor for both wild-type and vaccine strains of MV. 14, 15 PVRL4 is a member of adhesion receptors of the immunoglobulin superfamily and is normally localized to adherens junctions together with cadherins. It is mainly expressed in the placenta and slightly in the trachea. 16 Recent studies have shown that PVRL4 is not necessary for systemic spread and virulence of MV but is important for virus shedding into the airways. 15, 17 In addition, it has been reported to be a tumor cell marker for breast, lung and ovarian cancers. [18] [19] [20] MV has two envelope glycoproteins, the hemagglutinin (H) and fusion (F) proteins. The H protein interacts directly with the cellular receptors and triggers the F protein to execute membrane fusion. 4 In previous studies, H protein amino acids essential for interaction with its receptors have been identified, and the introduction of amino-acid substitutions at those positions resulted in the generation of recombinant MVs selectively blind to each receptor. 17, 21 In this study, we found that a wild-type MV HL strain 22 grew efficiently, resulting in cell death, in various breast cancer cell lines that did not express SLAM. Based on this finding, we generated a recombinant MV selectively blind to SLAM (rMV-SLAMblind) and investigated its potential as a novel therapeutic agent against breast cancer. rMV-SLAMblind decreased the viability of breast cancer cell lines, but did not affect the viability of SLAM-positive lymphoid cells. We showed that rMV-SLAMblind used PVRL4 as a receptor and not CD46, and infected CD46-positive normal human cells at a very low level. rMV-SLAMblind showed a greater oncolytic activity than that of a vaccine strain of the Edmonston lineage (rMV-Edmonston) in tumor-bearing mice. rMV-SLAMblind was found to be attenuated in measles-naïve monkeys. Our data suggest that rMV-SLAMblind may be a promising candidate therapeutic agent for breast cancer.
RESULTS
Efficient growth of wild-type MV in SLAM-negative breast cancer cell lines and generation of rMV-SLAMblind Wild-type MV HL strain efficiently infected and killed various human breast cancer cell lines including MCF7, MDA-MB-453 and SKBR3 cells (Figure 1a , upper panels). Wild-type MVs are known to use SLAM as the main receptor, 11 which is expressed in cells of the immune system. However, RT-PCR (reverse transcription PCR) and flow cytometric analysis indicated that these breast cancer cell lines were SLAM-negative (Figures 1b and c) . Thus, MV infection was occurring via a SLAM-independent mechanism. This finding suggested the possibility that a recombinant MV selectively unable to use SLAM would lose cytotoxicity to SLAM-positive immune cells, while retaining the oncolytic activity against breast cancer cells. Using a reverse genetics system for HL strain, 23 we generated SLAM-blind recombinant MVs by introducing a single amino-acid substitution 21 (R533A) into the H protein open reading frame (Figure 1d ). The SLAM-blind recombinant MV containing the enhanced green fluorescent protein (EGFP) gene (rMV-EGFPSLAMblind) infected SLAM-positive B95a cells at a very low efficiency, whereas it infected breast cancer cell lines as efficiently as the parental rMV-EGFP (Figure 1a) . Growth kinetics of rMVSLAMblind were compared with those of the parental virus (rMV) and a vaccine strain of the Edmonston lineage (rMV-Edmonston) in MCF7 cells (Figure 1e ). The rMV-SLAMblind grew more slowly than rMV, but the maximum titer was similar. The growth speed The EGFP gene or the firefly luciferase gene (luc) was inserted between the N and P genes. (e) MCF7 cells were infected with rMV, rMVSLAMblind or rMV-Edmonston at an MOI of 0.01, and infectious titers in culture medium (released virus) and cells (cell-associated virus) were determined at various time points. and the maximum titer of rMV-Edmonston were lower than those of rMV-SLAMblind.
rMV-SLAMblind uses PVRL4 and not CD46 to infect breast cancer cells In addition to SLAM, CD46 and PVRL4 have been identified as receptors for MV. CD46 is a receptor only for MV vaccine strains. PVRL4 has recently been identified as a receptor 14, 15 for both wildtype and vaccine strains of MV. Both molecules were expressed on the surface of breast cancer cell lines (Figure 2a) . Therefore, we performed an infection inhibition assay using anti-CD46 and anti-PVRL4 antibodies (Figure 2b ). The anti-CD46 antibody did not inhibit infection of breast cancer cells with rMV-EGFP and rMV-EGFP-SLAMblind, whereas the anti-PVRL4 antibody almost completely inhibited infection. The infection of breast cancer cells with rMV-Edmonston was not inhibited by either antibody alone, consistent with the fact that MV vaccine strains use both CD46 and PVRL4 as receptors. Vero cells, which are CD46-positive and PVRL4-negative, 14, 15 were efficiently infected only by rMV-Edmonston and infection was almost completely inhibited by anti-CD46 antibody. In addition, the infection efficiency of rMVEdmonston in MDA-MB-453 cells was lower than that of rMV-EGFP and rMV-EGFP-SLAMblind. To examine whether CD46 and PVRL4 act as entry receptors, we transfected plasmids encoding human CD46 (pCAG-hCD46) or human PVRL4 (pCAG-hPVRL4) into cells non-susceptible to MV, such as CHO-K1 and BHK cells. The infectivity of rMV-Edmonston was higher in cells transfected with pCAG-CD46 than in those transfected with the empty vector (pCAGGS), but the infectivity of rMV-SLAMblind and the parental virus did not differ between the two groups ( Figure 2c ). In contrast, all viruses showed a higher infectivity in cells transfected with pCAG-hPVRL4 than in control cells (Figure 2d ). These results indicated that rMV-SLAMblind and the parental virus used PVRL4 as a receptor and not CD46. rMV-SLAMblind shows greater oncolytic activity than rMV-Edmonston in human breast cancer xenografts rMV-SLAMblind and rMV-Edmonston were administered intratumorally to severe combined immune deficiency mice bearing subcutaneous MCF7 xenografts. Administration of both viruses (three doses of 10 5 TCID 50 (50% tissue culture infectious dose)) caused suppression of tumor growth, but rMV-SLAMblind caused a greater degree of suppression than rMV-Edmonston ( Figure 5a ). In MDA-MB-453 xenografts, intratumoral administration of both viruses (two doses of 10 6 TCID 50 ) also caused suppression of tumor growth, but rMV-SLAMblind suppressed tumor growth earlier than rMV-Edmonston (Figure 5b ). SKBR3 cells were unable to form tumors in mice (data not shown).
A luciferase-expressing SLAM-blind recombinant MV localizes and persists within human breast cancer xenografts To visualize virus localization in xenografted mice, we used a SLAM-blind recombinant MV expressing firefly luciferase (rMV-lucSLAMblind; Figure 1d ). MDA-MB-453 cells were implanted subcutaneously in 11 nude mice. Six mice received a single intratumoral administration of 10 6 TCID 50 of rMV-luc-SLAMblind and five mice received medium only (medium control). A further five nude mice were implanted with phosphate-buffered saline (PBS)/Matrigel mixture without cells and were subcutaneously administered with the virus at the same site (tumor-free control). Using D-luciferin as a substrate, we performed bioluminescence imaging (BLI). Strong and localized luminescence was detected in the xenografted mice administered with the virus (Figure 6a (Figures 6b and c) . Moreover, we performed combined bioluminescence and magnetic resonance imaging (MRI) at 10 d.p.i., as described previously. 25 The BLI/MRI fusion image of one mouse is shown in Figure 6e . Virus localization observed with BLI merged with tumor localization observed with MRI. These results demonstrated that virus replication was localized within the tumor.
rMV-SLAMblind is attenuated in monkeys To assess the in vivo safety, we subcutaneously inoculated 10 6 TCID 50 of rMV-SLAMblind into one cynomolgus and two rhesus monkeys that were confirmed to be seronegative for MV. After inoculation, the cynomolgus monkey was monitored for 1 month and the rhesus monkeys for 14 days. No clinical symptoms of SLAM-blind measles virus for breast cancer treatment T Sugiyama et al measles including anorexia, diarrhea and rash were observed in any of the monkeys (Figure 7a ). No meaningful effects on body weight were seen (Figure 7b ). Virus levels in peripheral blood mononuclear cells (PBMCs) were below the lower detection limits (Figure 7a ) and lymphocyte numbers were not decreased after virus inoculation (Figure 7c) . Although a transient increase in neutrophil number was observed at 0 d.p.i. in the cynomolgus monkey, it was regarded as irrelevant because the blood had been collected before virus inoculation. These results are in contrast to those reported for the parental wild-type MV HL strain and other wild-type MV strains, which cause typical clinical symptoms of measles, viremia and lymphopenia in infected monkeys. 22, [26] [27] [28] [29] These results show that rMV-SLAMblind is attenuated in vivo.
DISCUSSION
To develop an oncolytic MV for potential clinical use, we generated rMV-SLAMblind, and demonstrated that it was attenuated in monkeys. Previous studies of patients and infected monkeys have indicated that the distribution of SLAM is well correlated with sites of MV spread in vivo, 30 and SLAM-positive T and B lymphocytes are the major target of MV. 31 It has been suggested that most MV pathology, including lymphopenia and immunosuppression, can be explained by the utilization of SLAM by MV. Therefore, a recombinant MV unable to use SLAM would be attenuated. This prediction was confirmed by the result that no clinical evidence of disease was documented in monkeys infected with rMV-SLAMblind (Figure 7) , proving that efficient SLAM recognition was necessary for virulence. It has previously been reported that a recombinant wild-type MV IC-B strain, with an R533A substitution introduced into the H protein, was attenuated in rhesus monkeys. 32 The SLAM-blind IC-B virus did not cause measles-like symptoms in any of the six inoculated monkeys, although low-level viremia was detected in only one. These data may support our results because the IC-B strain genome has a 499.7% nucleotide homology with that of the HL strain. Moreover, we note that rMV-SLAMblind has two nucleotide mutations introduced to change an arginine to alanine. Thus, it is considered to be a safer virus than those with single nucleotide mutations.
Our data show that both rMV-SLAMblind and the parental MV HL strain (rMV) use PVRL4 and not CD46 as a receptor. The MV HL strain is a wild-type strain isolated from blood leukocytes of a measles patient using marmoset lymphoblastoid B95a cells, in which it was propagated. Thus, it is consistent with previous findings that wild-type MV strains cannot use CD46 as a receptor, 30 but can use PVRL4. 14, 15 CD46 is frequently overexpressed in tumors 33 and MV Edmonston vaccine strain derivatives preferentially kills cells with high CD46 density. 34 Therefore, it has been investigated as a therapeutic agent against various types of cancer. However, our results indicated that the use of CD46 was not required for the oncolytic activity of 
rMV-SLAMblind against the breast cancer cell lines. In fact, CD46 is ubiquitously expressed by all normal human cells except erythrocytes, 35 and an MV Edmonston strain previously used for oncolysis was reported to efficiently infect and kill NHDFs, 24 producing syncytia. In contrast, rMV-SLAMblind infected them minimally (Figure 3) . Therefore, rMV-SLAMblind, which is both SLAM-and CD46-blind, may have an important advantage in terms of improved specificity for PVRL4-positive breast cancer cells. Moreover, the previously reported MV Edmonston strain for breast cancer treatment 7 has an unmodified H protein, which can interact with all known MV receptors: SLAM, CD46 and PVRL4.
Previous studies have shown that PVRL4 is highly expressed in tumors of breast origin but scarcely expressed in normal tissues except placenta. 16, 20, 36 In breast tumor samples, PVRL4 expression was shown to be negatively correlated with luminal-like markers and positively with basal-like markers and HER2. 20, 36 In addition, increased PVRL4 expression was strongly correlated with increased grade, increased tumor size, increased lymph nodes infiltration and reduced survival. 36 Thus, it is possible that rMVSLAMblind could be effective against aggressive types of breast cancer. Furthermore, because PVRL4 has been shown to be upregulated in lung and ovarian cancers, 18, 19 rMV-SLAMblind may also be useful for their treatment.
The rMV-SLAMblind showed greater oncolytic activity than did rMV-Edmonston. In MDA-MB-453 cells, oncolytic activity of rMVSLAMblind was greater in vitro and in vivo (Figures 4d and 5b) . However, in MCF7 cells, rMV-SLAMblind showed in vitro cytotoxicity similar to that of rMV-Edmonston, but was more effective for tumor growth suppression in vivo (Figures 4c and 5a ). This might have been due to differences between the in vitro culture conditions and the in vivo environment, where factors such as stromal architecture and surrounding innate immune system could limit virus spread. Previous comparative studies between wild-type and Edmonston vaccine strains have indicated important properties of wild-type MVs, including evasion of the intracellular innate immune response 37, 38 and enhanced virus replication. 39 These factors could account for the enhanced oncolytic activity of rMV-SLAMblind. Analyses of the underlying mechanisms are currently ongoing.
The rMV-Edmonston used in this study was not identical to the Edmonston strain derivative previously used for breast cancer treatment (MV-CEA). 7 MV-CEA had an additional transcription unit encoding carcinoembryonic antigen (CEA) as a trackable marker of viral gene expression. In addition, we found that the plasmid p( þ )MV2A, from which we rescued rMV-Edmonston, had 12 nucleotide and 5 amino-acid differences from the reported sequence data for the infectious complementary DNA (cDNA) clone of the Edmonston B strain (GenBank accession no. Z66517) (see Materials and methods for details). Therefore, in terms of oncolytic activity we cannot directly compare our data with those of MV-CEA. However, these differences do not affect our conclusion that rMV-SLAMblind has improved tumor specificity, because all strains of the Edmonston lineage use CD46.
A major obstacle for MV-based vectors is the presence of preexisting anti-MV antibodies in patients, which can reduce therapeutic efficacy. A previous study has demonstrated that, when administered intratumorally, the efficacy of oncolytic MV is not compromised by the presence of passively transferred anti-MV antibody in a mouse model. 40 This means that, once virus reaches the tumor, regression may take place even in the presence of antibodies. Although the final goal is to eradicate metastasized cancer cells by intravenous virus administration, the treatment of localized tumor with intratumoral virus administration is a logical first step. We are now exploring strategies to evade neutralization of intravenously administered virus by preexisting antibodies. One possible strategy is to hide virus antigens from antibodies by using cells as delivery vehicles. 41 In this strategy, the body's cells are infected in vitro and then administered back systemically, which would carry the oncolytic virus to target tumor cells. Recent studies have shown that cells infected with oncolytic MV can deliver viruses to tumor sites and prolong survival of tumorbearing mice with pre-existing anti-measles antibodies. 42, 43 In a previous study, virus replication and fusogenic activity in PVRL4-expressing cells was enhanced by introducing a single N481F or N481Y substitution into the H protein of a wild-type IC-B stain, without affecting SLAM or CD46-dependent cell-cell fusion. 44 The H protein of HL strain also has asparagine at position 481. Thus, by introducing the same substitution, we can probably enhance the oncolytic activity of rMV-SLAMblind without affecting its receptor usage. Moreover, H proteins of MV strains of the Edmonston lineage already have tyrosine at position 481, and thus this strategy is not applicable.
In conclusion, we have generated rMV-SLAMblind and demonstrated that it had oncolytic activity against breast cancer xenografts and was attenuated in monkeys. The rMV-SLAMblind did not interact with CD46 and showed greater oncolytic activity than that of rMV-Edmonston. These results point to the potential of rMV-SLAMblind as a novel oncolytic virus for breast cancer treatment, which warrants further investigation.
MATERIALS AND METHODS Cells
B95a, CHO-K1, Vero and 293 cells have been described previously. 
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St Louis, MO, USA) with 5% FBS. BHK cells were grown in Dulbecco's Modified Eagle's Medium (Sigma-Aldrich) with 5% FBS. NHDFs were purchased from Cell Systems (Kirkland, WA, USA) and maintained in CS-C medium (Cell Systems) supplemented with CSC growth factor (Cell Systems) and 5% FBS.
Recovery of recombinant MVs
The pMV-HL(7 þ ) plasmid encodes the full-length antigenomic cDNA of MV HL wild-type strain. 23 The pMV-EGFP and pMV-LUC, which have an additional transcription unit encoding EGFP and firefly luciferase (luc) genes, have been reported previously. 23, 45 The R533A substitution was introduced into pMV-HL(7 þ ), pMV-EGFP and pMV-LUC by site-directed mutagenesis and the resultant plasmids were designated as pMVSLAMblind, pMV-EGFP-SLAMblind and pMV-luc-SLAMblind, respectively. The plasmid p( þ )MV2A (a gift from MA Billeter) encodes the full-length antigenomic cDNA of the Edmonston B vaccine strain. 47 We found that the p( þ )MV2A had the following nucleotide differences from the reported sequence data for the Edmonston B strain (GenBank accession no. Z66517): A3310G, C3627T, C4708T, T5703A, A5737G, C6414T, A6477G, T6546C, T7023C, T8353C, A8721C and A8745G. Five of them caused aminoacid changes in the P (M502V), M (P64S), F (M97V) and H (N484T and E492G) proteins.
The recombinant MV HL (rMV) and rMV-EGFP were recovered as described previously. 23 To recover SLAM-blind recombinant MVs, MCF7 cells were used for virus amplification owing to the restricted receptor usage of the virus. The rescued virus from p( þ )MV2A was referred to as rMV-Edmonston. To recover rMV-Edmonston, Vero cells were used for virus amplification.
Virus titers
Virus titers were determined as 50% tissue culture infectious dose (TCID 50 ) by the Reed-Muench method. 48 The titers of SLAM-blind recombinant MVs SLAM-blind measles virus for breast cancer treatment T Sugiyama et al could be determined only in PVRL4-expressing cells, owing to receptor usage restriction, and were therefore titrated in MCF7 cells. MV infection in MCF7 cells was detected by fluorescence of EGFP or indirectly by immunostaining using anti-N protein monoclonal antibody (MAb) 8G 49 as a primary antibody and Alexa-Fluor-488-conjugated anti-mouse antibody (Invitrogen) as a secondary antibody. We note that titers of rMV and rMV-EGFP determined in MCF7 cells were similar to those determined in B95a cells, and titers of rMV-Edmonston determined in MCF7 cells were similar to those determined in Vero cells.
RT-PCR analysis
Total RNA was extracted from cells using ISOGEN (Nippon Gene, Tokyo, Japan) and 2 mg total RNA was reverse transcribed using PrimeScript RTase (Takara, Shiga, Japan) by random hexamer priming. The resultant cDNA was PCR-amplified using Thermo-start Taq DNA polymerase (ABgene, Epsom, UK) with primer pairs specific for SLAM or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA. PCR amplicons were visualized on agarose gels.
Growth kinetics
Monolayers of MCF7 cells in 12-well plates were infected with recombinant MVs at an MOI of 0.01 and incubated in RPMI medium supplemented with 5% FCS. At various time points, released virus was obtained from the culture supernatants, and cell-associated virus was recovered from infected cells by three cycles of freezing-thawing. Virus titers were determined in MCF7 cells.
Infection inhibition assay using antibodies
Monolayers of MCF7, MDA-MB-453, SKBR3 and Vero cells in 96-well plates were pretreated for 1 h at 37 1C with medium containing 10 mg ml Infection assay on cells transfected with plasmids expressing CD46 and PVRL4 Human CD46 cDNA (C2 isoform) and human PVRL4 cDNA were obtained by RT-PCR of total RNA from 293 and MCF7 cells, respectively. The cDNAs were subcloned into pCAGGS. 51 The resultant plasmids were designated pCAG-hCD46 and pCAG-hPVRL4.
For the transfection of pCAG-hCD46, CHO-K1 cells were seeded in a 6-well plate and were transfected with either pCAG-hCD46 or pCAGGS. 
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After overnight incubation, the cells were detached from the plate by trypsin treatment and seeded in a 96-well plate. On the following day, cells were infected with rMV-SLAMblind or rMV-Edmonston at an MOI of 1 for 1 h at 37 1C. The virus inoculum was replaced with medium containing fusion inhibitory peptide (z-D-Phe-Phe-Gly; Sigma-Aldrich) to prevent cellcell fusion and infection by virus progeny. Incubation was continued at 37 1C for 2 days and cells were fixed with 4% paraformaldehyde and immunostained using anti-N MAb. The number of infected cells per well was counted under a fluorescent microscope. Relative infectivity in cells transfected with pCAG-hCD46 or pCAGGS was calculated as the mean of triplicate counts divided by the mean of triplicate counts in cells transfected with pCAGGS and was expressed as a percentage.
For transfection of pCAG-hPVRL4, we used BHK cells because CHO-K1 cells died after transfection with pCAG-hPVRL4. BHK cells were transfected with pCAG-hPVRL4 or pCAGGS as described above and infected with rMVSLAMblind or rMV-Edmonston at an MOI of 0.1. Relative infectivity in cells transfected with pCAG-hPVRL4 or pCAGGS was determined as above.
WST-1 assay . Fusion images of BLI and MRI were acquired as described previously. 25 Inoculation of rMV-SLAMblind into monkeys A 4-year-old female cynomolgus monkey (Macaca fascicularis) and two 15-month-old male rhesus monkeys (Macaca mulatta) were obtained from Japan Wild Animal Research (Kagoshima, Japan) and were confirmed as seronegative for MV. The monkeys were inoculated subcutaneously with 10 6 TCID 50 of rMV-SLAMblind.
Leukocyte numbers
In all, 100 ml of peripheral blood was collected at various time points. Leukocyte numbers were counted using an automated hematological analyzer (model KX-21NV; Sysmex, Kobe, Japan). The percentages of lymphocytes, neutrophils, eosinophils, basophils and monocytes were determined on a Giemsa-stained thin blood smear.
Virus levels in PBMCs
In all, 2 ml of peripheral blood was collected at 2, 4, 7, 14 and 21 d.p.i. The blood was diluted to 10 ml in PBS, layered on 3 ml of gradient separation medium (49.2% Percoll and 150 mM NaCl) and centrifuged at 400 Â g for 30 min at room temperature. PBMCs were recovered at the interface. After washing twice with PBS, cells were resuspended in 2 ml RPMI medium. Virus levels were quantified by end-point dilution coculture with MCF7 cells. Serial 10-fold dilutions of PBMCs were made in RPMI medium supplemented with 5% FBS. Four replicates of PBMCs were cocultured with MCF7 cells in 96-well plates. The cultures were maintained for 7 days and immunostained using anti-N MAb for virus titration.
Flow cytometry
Cells were stripped with 2 mM EDTA and then pelleted by centrifugation at 200 Â g. The pelleted cells were resuspended in sample buffer (PBS with 1% bovine serum albumin and 0.02% NaN 3 ). Cells (10 6 ) were incubated with 0.5 mg of primary antibody in 100 ml of sample buffer on ice for 30 min. The following antibodies were used as primary antibodies: anti-human SLAM MAb (clone 7D4; Biolegend, San Diego, CA, USA), anti-human CD46 MAb, anti-PVRL4 goat polyclonal antibody (R&D Systems), mouse control IgG1 (R&D Systems) and goat control IgG (R&D Systems). Cells were washed once with PBS and incubated with 0.1 mg of Alexa-488-conjugated antimouse or anti-goat antibody (Invitrogen) in 100 ml of sample buffer on ice for 30 min. After being washed twice with PBS, cells were fixed with 4% paraformaldehyde and analyzed on a BD FACSCalibur (BD Biosciences).
